See Supplemental Patient Information
- Therapy is not recommended for complications of radiation exposure. Radiation toxicity including bone marrow suppression with severe neutropenia and thrombocytopenia may develop in patients contaminated with high doses of 137Cs. Supportive treatment should be given concomitantly with therapy to avoid radiation toxicity
- Constipation has been reported with therapy, in such cases patient should be treated with fiber based laxative and/or a high fiber diet. Use cautiously in patients with disorders associated with decreased gastrointestinal motility
- Asymptomatic hypokalemia, with serum potassium values of 2.5-2.9 has been reported in patients treated with radiogardase. Closely monitor serum electrolytes during treatment. Use cautiously when treating patients with pre-existing cardiac arrhythmias or electrolyte imbalances
Cautions: Use cautiously in
- Decreased gastrointestinal motility disorder
- Pre-existing cardiac arrhythmias
- Electrolyte imbalance
Supplemental Patient Information
- Advise patient to take safety precautions to reduce radiation exposure to Cesium-137; take extra precautions in handling urine or feces and wash hands thoroughly after contact; flush toilet several times after each use; clean up spilled urine or feces completely; wash contaminated clothing separately
- Inform patient receiving radiogardase that their stools might be blue-colored
Pregnancy Category:C
Breastfeeding: Excretion of ferric hexacyanoferrate in breast milk is not known, but would not be expected. Cesium and thallium are excreted in breast milk; internally contaminated mothers should not breast-feed.
